Unmet needs, uncommon commitment: The shift toward investment in rare diseases

January 19, 2017 Erin Righetti

Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candid, interactive and enlightening panel discussion about the evolving landscape in rare disease drug discovery and development. The panel discuss how approaches to rare disease research, drug development, commercialization and investment have changed in recent years, and why and how they’ve chosen to pursue leadership and innovation in rare diseases.


Moderator: Alison Silva – Critical Outcome Technologies

  • Debra Miller – CureDuchenne
  • Henri Termeer – Formerly Genzyme; Aura Biosciences
  • Phil Vickers – Shire
  • Flemming Ornskov – Shire

About the Author

Erin Righetti

Editor-in-Chief, Insight

Follow on Twitter More Content by Erin Righetti
Previous Article
Industry pundit Joe Hage on medtech innovation in 2017
Industry pundit Joe Hage on medtech innovation in 2017

Joe Hage, a medical device marketing consultant, is well known in medtech circles. In particular, he runs o...

Next Article
The renaissance of gene therapy
The renaissance of gene therapy

Gene therapy and gene editing are at the beginning of a renaissance, according to speakers at Biotech Showc...